Study Shows 14-Month Survival, Some Heart AEs for Breast Cancer Patients on Tykerb/Herceptin Combo

The Phase III study, presented last week at the San Antonio Breast Cancer Symposium, involved 296 women with HER2-positive breast cancer whose cancer had recurred despite receiving a median of three previous Herceptin-based treatments. "The data presented at the San Antonio congress showed that patients overcame resistance to [Herceptin] with the introduction of the [Tykerb/Herceptin] combination," GSK said in a statement.